MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.21 -1.63

Buy Sell

Overview

Share price change

24h

Current

Min

1.19

Max

1.21

Key metrics
By Trading Economics
Income	-124K -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-2,364.792
Employees	161
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+81.45% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-43M 131M
Previous open	2.84
Previous close	1.21

News Sentiment

By Acuity

54%

46%

296 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 kwi 2026, 17:11 UTC

Major Market Movers

Major News Events

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2 kwi 2026, 17:10 UTC

Major News Events

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

3 kwi 2026, 00:00 UTC

Major News Events

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2 kwi 2026, 23:47 UTC

Market Talk

Major News Events

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2 kwi 2026, 21:01 UTC

Major News Events

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2 kwi 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

Starbucks and Boyu Capital Finalize China JV

2 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

2 kwi 2026, 20:41 UTC

Earnings

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 kwi 2026, 20:32 UTC

Market Talk

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2 kwi 2026, 20:30 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 kwi 2026, 20:09 UTC

Market Talk

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2 kwi 2026, 20:01 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 kwi 2026, 19:46 UTC

Market Talk

Is Oil the New GameStop? -- Market Talk

2 kwi 2026, 19:35 UTC

Market Talk

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2 kwi 2026, 19:29 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 kwi 2026, 19:24 UTC

Market Talk

Major News Events

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2 kwi 2026, 19:20 UTC

Market Talk

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2 kwi 2026, 19:01 UTC

Acquisitions, Mergers, Takeovers

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2 kwi 2026, 19:00 UTC

Acquisitions, Mergers, Takeovers

Union Pacific: Agreement Reached With American Train Dispatchers Association

2 kwi 2026, 18:24 UTC

Acquisitions, Mergers, Takeovers

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2 kwi 2026, 17:44 UTC

Market Talk

Major News Events

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2 kwi 2026, 17:32 UTC

Major News Events

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2 kwi 2026, 17:26 UTC

Earnings

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 kwi 2026, 17:17 UTC

Market Talk

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2 kwi 2026, 17:09 UTC

Market Talk

Major News Events

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

81.45% upside

12 Months Forecast

Average 2.25 USD 81.45%

High 2.5 USD

Low 2 USD

Based on 4 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

296 / 349 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.